Free Trial
Your Rate Never Goes Up! Save $100 a Year on MarketBeat All Access
Upgrade Now
Claim MarketBeat All Access Sale Promotion
NASDAQ:VCNX

Vaccinex Earnings Date & Estimates

Vaccinex logo
$0.70 0.00 (0.00%)
As of 10/20/2026 02:14 PM Eastern

Vaccinex is estimated to report earnings on Monday, November 16, 2026.

Research:Profile

Upcoming Earnings Announcement

Announcement Date
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Vaccinex

Vaccinex is expected to post earnings of -$73.0380 per share on revenue of $0.33 million.

Consensus Estimates

Consensus EPS
-$73.0380
Expected Revenue
$0.33 million

Recent Track Record

Last Reported
Q2 2024
Last Quarter EPS
-$3.10
Last Quarter Revenue
$0.23 million

Prepare for the Earnings Call

Vaccinex Earnings FAQ

Vaccinex (NASDAQ:VCNX) is estimated to report earnings on Monday, November 16, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Analysts expect Vaccinex to post earnings of -$73.0380 per share for the quarter.

The consensus revenue estimate for Vaccinex is $0.33 million for the quarter.

Vaccinex Earnings Headlines

SEMA4D Blockade Reshapes the Tumor Immune Environment in Neoadjuvant Melanoma Study
October 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/07/3376451/34858/en/sema4d-blockade-reshapes-the-tumor-immune-environment-in-neoadjuvant-melanoma-study.html
Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer's Association International Conference in London on July 13, 2026
July 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/08/3324070/34858/en/vaccinex-to-report-new-biomarker-data-and-plans-for-phase-2b-clinical-trial-of-pepinemab-in-ad-at-the-alzheimer-s-association-international-conference-in-london-on-july-13-2026.html
Ticker Revealed: Pre-IPO Access to "Next Elon Musk" Company
We’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.tc pixel
October 21 at 1:00 AM  |  Banyan Hill Publishing (Ad)
Vaccinex, Inc. Reports Financial Results for Year Ended December 31, 2025
April 29, 2026  |  quiverquant.comQ
Vaccinex Reports 2025 Annual Financial Results
April 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/30/3284388/34858/en/vaccinex-reports-2025-annual-financial-results.html
Vaccinex Inc.
April 10, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/vcnx/company-people
See More Vaccinex Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vaccinex? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vaccinex and other key companies, straight to your email.

About Vaccinex

Vaccinex (NASDAQ:VCNX) is a clinical-stage biotechnology company headquartered in Rochester, New York. The company develops antibody-based therapies for serious diseases, with a focus on conditions involving neurodegeneration, cancer and immune-system dysfunction.

Vaccinex’s lead product candidate is pepinemab, also known as VX15/2503, a humanized monoclonal antibody designed to block Semaphorin 4D (SEMA4D). The company has evaluated pepinemab in clinical studies for Huntington’s disease and Alzheimer’s disease, as well as in oncology programs, including research investigating its potential use in combination with other cancer treatments.

Vaccinex also maintains antibody-discovery and development capabilities intended to support the creation of additional therapeutic candidates and potential collaborations. The company’s programs are developed through clinical research conducted in the United States and in collaboration with academic and industry partners. Vaccinex was co-founded by Maurice Zauderer, Ph.D., who has served as its president and chief executive officer.

View Vaccinex Profile
Earnings Tools